Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment

Publisher： Karger

E-ISSN： 1421-9794|62|1|80-84

ISSN： 0009-3157

Source： Chemotherapy, Vol.62, Iss.1, 2016-09, pp. : 80-84

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen

By Silvestris Nicola Simone Giovanni Partipilo Giulia Scarpi Emanuela Lorusso Vito Brunetti Anna Elisabetta Maiello Evaristo Paradiso Angelo Mangia Anita

International Journal of Molecular Sciences, Vol. 15, Iss. 9, 2014-09 ,pp. : 15767-15777

MDPI

Access to resources Recommend Favorite

Safety and Efficacy of Modified FOLFOX6 plus High-Dose Bevacizumab in Second-Line or Later Treatment of Patients with Metastatic Colorectal Cancer

Chemotherapy, Vol. 59, Iss. 2, 2013-07 ,pp. : 79-84

Karger

Access to resources Recommend Favorite

Irinotecan-Cetuximab-Bevacizumab as a Salvage Treatment in Heavily Pretreated Metastatic Colorectal Cancer Patients: A Retrospective Observational Study

Chemotherapy, Vol. 57, Iss. 2, 2011-03 ,pp. : 138-144

Karger

Access to resources Recommend Favorite

Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer

Chemotherapy, Vol. 56, Iss. 2, 2010-04 ,pp. : 142-146

Karger

Access to resources Recommend Favorite

Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis

Chemotherapy, Vol. 61, Iss. 1, 2015-0 ,pp. : 41-50

Karger

Access to resources Recommend Favorite